
AFTER JULIE SIMONSON SURVIVED A SEXUAL assault, she turned to the 7-Eleven across the street for comfort food. Her weight skyrocketed, along with her shame.
"I would cope by basically overeating," the psychotherapist from Philadelphia says, recalling how her health declined in the aftermath of the attack.
Eventually she turned to gastric bypass surgery and lost 160 pounds. Simonson, 50, endured skin removal surgery, a tummy tuck and an arm lift, but the pounds slowly came back, despite her best efforts to restrict calories and work with a trainer.
Finally, in 2023, Simonson's doctor put her on Mounjaro, one of the new class of highly touted diabetes and weight-loss drugs, and the pounds finally came off and stayed off. She says she feels amazing.
But beneath Simonson's joy, she's found a darker side to living at a healthy weight-people are treating her like a celebrity, even though she's the same person she's always been.
"My interests haven't changed. My sense of humor hasn't changed. Fundamentally who I am hasn't changed," Simonson says indignantly. "That's why it's frustrating when people are nicer to me because I'm not really any different."
As tens of millions of Americans reap the benefits of new obesity therapies, some are finding a bitter confirmation of the fatphobia they've experienced all their lives-and are grappling with how to deal with theirr own, internal bias now that they're "on the other side."
It's yet another aspect of a new health and weight revolution powered by a class of drugs called GLP-1 agonists that's reshaping American society.
As many Americans lose weight to improve their health, their old bodies-and memories of past mistreatment-continue to cast a shadow over them.
They're learning all over, in a new way, how awful neighbors, co-workers and strangers can be.
ãã®èšäºã¯ Newsweek US ã® August 16 - 23, 2024 (Double Issue) çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã9,000 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã ?  ãµã€ã³ã€ã³
ãã®èšäºã¯ Newsweek US ã® August 16 - 23, 2024 (Double Issue) çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã9,000 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã? ãµã€ã³ã€ã³

Slimmer Side Effects
Weight-loss drugs have become hugely popular but can cause gastrointestinal issues. A breakthrough could be about to change that and also make treatment more affordable

AMERICA'S BEST NEW PRODUCTS 2025
VERY YEAR, COMPANIES PUSH THE BOUNDARIES OF CREATIVity and develop new products that promise to make your life healthier, more convenient and more fun.

HIGH WIRE ACT
FAULTY POWER LINES AND ELECTRICAL EQUIPMENT ARE BEING BLAMED FOR CAUSING DEADLY FIRES IN LOS ANGELES AND ACROSS THE U.S. IS ENOUGH BEING DONE TO PREVENT THESE DEVASTATING BLAZES?

Chelsea Handler
AS A SIX-TIME NEW YORK TIMES BESTSELLING AUTHOR, CHELSEA HANDLER knows the secret to a successful book is to stay true to herself.

Stephen Amell
WHILE IT SEEMED LIKE EVERYONE ON SOCIAL media was binge-watching Suits during the pandemic, there was one person who was intentionally not watching the long-running series that ended in 2019: Stephen Amell.

Not Seeing...But Believing
How COVID reshaped our understanding of invisible air particles and the spread of disease

The Strongman of Ecuador
Daniel Noboa's bravado, aggressive policies and alignment with Trumpian politics has positioned him as a formidable figure in Latin America. But his fight to retain the presidency isn't over

Spheres of Influence
Donald Trump is channeling the great power politics of past centuries to deal with China and Russia, experts tell Newsweek

AMERICA'S BEST LOYALTY PROGRAMS 2025
LOYALTY PROGRAMS HAVE BECOME A CORNERSTONE of the modern shopping experience, offering perks and rewards designed to keep customers returning for more.

Winning the Global Game
The U.S. holds more cards than China. Whether we keep our strategic advantage depends on how we play our hand